Literature DB >> 9952222

Respiratory distress during mesalamine therapy.

M Guslandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9952222     DOI： 10.1023/a:1026641830958

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  4 in total

1.  Mesalazine alveolitis.

Authors:  T Welte; H Hamm; H Fabel
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

2.  Adverse pulmonary effects of mesalamine.

Authors:  A Muzzi; F Ciani; D Bianchini; G Festini; C Volpe
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

3.  [Iatrogenic diffuse interstitial pneumonia linked to 5-aminosalicylate].

Authors:  D Declerck; B Wallaert; G Demarcq-Delerue; A B Tonnel
Journal:  Rev Mal Respir       Date:  1994       Impact factor: 0.622

Review 4.  Mesalamine-induced lung toxicity.

Authors:  A Bitton; M A Peppercorn; J P Hanrahan; M P Upton
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864
  4 in total
  3 in total

1.  Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Authors:  José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 2.  Pulmonary involvement and allergic disorders in inflammatory bowel disease.

Authors:  Nikolaos E Tzanakis; Ioanna G Tsiligianni; Nikolaos M Siafakas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

3.  Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation.

Authors:  Hajime Oi; Atsushi Suzuki; Yasuhiko Yamano; Toshiki Yokoyama; Toshiaki Matsuda; Kensuke Kataoka; Yasuhiko Suzuki; Tomoki Kimura; Yasuhiro Kondoh
Journal:  Respir Med Case Rep       Date:  2020-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.